Novelion Therapeutics completes reverse stock split

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
In PersonPolitics & Policy Live: Trade and Sustainability Amidst Volatile Markets
- 04/04/2023
- Convene, 1201 Wilson Blvd, Arlington, VA 22209
- 3:30 PM – 6:30 PM ET
WebinarThe Private Equity Landscape under review: The Middle East and Africa story in 2023
- 04/05/2023
- Live, Online
- 10:00 am - 11:00 am BST
WebinarManaging Investment Risk Amid Market Uncertainty
- 04/05/2023
- Live, Online
- 11:00 am - 12:00 am EST
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Perspectivas América Latina 2023 Emerging Trends & Growth

Blog

Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in

Blog

A Cloud Migration Plan for Corporations featuring Snowflake®

Blog

Investor Activism Campaigns Hit Record High in 2022

19 Dec, 2016 | 04:42

Author Jonathan Chan
Theme Healthcare & Pharmaceuticals

Novelion Therapeutics Inc. completed a planned 1-to-5 reverse stock split.

The company will now have 18,530,700 shares issued and outstanding with trading to resume on Nasdaq on Dec. 19 and the Toronto Stock Exchange on Dec. 21.